Marshall Wace’s PharmaCyte Biotech PMCB Stock Holding History

Marshall Wace’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-13,515	Closed	-$35K	–	3872
2021 Q4	$35K	Buy	+13,515	New	+$37.2K	﹤0.01%	3632

Other funds holding PMCB

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EPM

Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Marshall Wace's PMCB Position: Q1 2022 in Review

Marshall Wace sold out of PharmaCyte Biotech (PMCB) in Q1 2022, closing a stake of 13,515 shares — an estimated $35K sold.

Marshall Wace first reported a position in PMCB in Q4 2021 and held it in 1 quarter. The position peaked at $35K in Q4 2021. 25 funds tracked by Wall St. Rank hold PMCB as of Q1 2022.

Marshall Wace reported no remaining PharmaCyte Biotech position as of Q1 2022 after selling out during the quarter.
Marshall Wace sold 13,515 PharmaCyte Biotech shares in Q1 2022, an estimated $35K.
Marshall Wace first reported a position in PharmaCyte Biotech in Q4 2021 and held it in 1 quarter.
Marshall Wace's PharmaCyte Biotech position peaked at $35K in Q4 2021.
25 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q1 2022.

Based on Marshall Wace's 13F filing for Q1 2022, filed 16 May 2022.